Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-21
2011-11-01
Chong, Yong (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S423000, C514S171000
Reexamination Certificate
active
08048910
ABSTRACT:
Novel combinations based on anticholinergics, β2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases. A particular combination comprises R,R-glycopyrrolate, rolipram, and budesonide, or physiologically acceptable salts thereof, wherein dosage amounts are such that a synergistic therapeutic effect is achieved.
REFERENCES:
patent: 5712298 (1998-01-01), Amschler et al.
patent: 6086914 (2000-07-01), Weinstein et al.
patent: 6204285 (2001-03-01), Fabiano et al.
patent: 6384038 (2002-05-01), Rubin
patent: 6475467 (2002-11-01), Keller et al.
patent: 6645466 (2003-11-01), Keller et al.
patent: 7258118 (2007-08-01), Goede et al.
patent: 2001/0025040 (2001-09-01), Poppe et al.
patent: 2001/0027789 (2001-10-01), Goede et al.
patent: 2002/0115681 (2002-08-01), Bozung et al.
patent: 2002/0151597 (2002-10-01), Banerjee et al.
patent: 2003/0068280 (2003-04-01), Bannister et al.
patent: 2003/0119802 (2003-06-01), Gavin
patent: 2004/0002548 (2004-01-01), Bozung et al.
patent: 2004/0028734 (2004-02-01), Bannister et al.
patent: 2004/0038958 (2004-02-01), Rundfeldt et al.
patent: 2004/0053902 (2004-03-01), Smith
patent: 2005/0288265 (2005-12-01), Locher et al.
patent: 2006/0081246 (2006-04-01), Goede et al.
patent: 2006/0147382 (2006-07-01), Bundschuh et al.
patent: 1449528 (2004-08-01), None
patent: WO-01/76575 (2001-10-01), None
patent: WO-02/069945 (2002-09-01), None
patent: WO-02078671 (2002-10-01), None
patent: WO-02/096423 (2002-12-01), None
patent: WO-02/096463 (2002-12-01), None
patent: WO-03/011274 (2003-02-01), None
patent: WO 2004019984 (2004-03-01), None
patent: WO-2004084897 (2004-10-01), None
patent: WO-2005005999 (2005-06-01), None
Mueller et al. “Development of powder for inhalation with R,R-glycopyrrolate as active ingredient for the delivery from novel multidose dry powder inhaler,” European Respiratory Society Annual Congress 2003, Sep. 2003, abstract 2977.
Pahl, Andreas, Possible Synergistic Effects f R, S/S,R-glycopyrolate and Tiotropium with the Glucocorticoid Budesonide, Viatris: No. 2006-03, Jul. 19, 2006.
Austen et al. at p. 856 (Austen et al., Samter's Immunologic Diseases. Philadelphia: Lippincott Williams & Wilkins, 2001, pp. 855-856.
Brostoff et al., Clinical Immunology. London: Gower Medical Publishing, 1991, p. 17.1.
Gennaro, Alfonso. Remington's: Pharmaceutical Sciences. Easton, PA:Mack Publishing Co., 1985, p. 728.
Roitt et al. Immunology. 3rd Ed. St Louis: Mosby, 1993, p. 19.13.
Herbst et al., “Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a Phase I trial” Journal of Clinical Oncology, Sep. 15, 2002, vol. 20, No. 18. pp. 3815-3825.
Finsnes et al., “Leukotriene antagonism reduces the generation of endothelin-I and interferon-gamma and inhibits eosinophilic airway inflammation” Respiratory Medicine 2002, vol. 96, pp. 901-906.
Reid, P., “Roflumilast”, Current Opinion in Investigational Drugs, Current Drugs, London, GB, vol. 3, No. 8, Aug. 2002, pp. 1165-1170.
Santing et al., “Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs”, European Journal of Pharmacology, vol. 275, No. 1, pp. 75-82 (1995).
International Search Report dated Nov. 23, 2005, issued in PCT/EP2005/000649.
Bauhofer Artur
Cnota Peter Jürgen
Kastrup Horst
Maus Joachim
Szelenyi Istvan
Chong Yong
Haddaway Keith G.
Karol Jody
Meda Pharma GmbH & Co. KG
Venable LLP
LandOfFree
Combination of R,R-glycopyrrolate, rolipram, and budesonide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of R,R-glycopyrrolate, rolipram, and budesonide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of R,R-glycopyrrolate, rolipram, and budesonide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4311484